Content about methylphenidate hydrochloride

July 11, 2013

The Food and Drug Administration has approved a Kremers Urban Pharmaceuticals drug for treating attention deficit hyperactivity disorder, the UCB subsidiary said.

PRINCETON, N.J. — The Food and Drug Administration has approved a Kremers Urban Pharmaceuticals drug for treating attention deficit hyperactivity disorder, the UCB subsidiary said.

KU announced the approval of methylphenidate hydrochloride extended-release tablets in the 18-mg and 27-mg strengths.

The drug is a generic version of Johnson & Johnson's Concerta QD.

April 24, 2013

A dramatic jump in the rates of misuse of prescription stimulants over the past four years is linked to lax attitudes on the part of parents, according to a new study, though misuse and abuse of prescription opioids has remained flat.

NEW YORK — A dramatic jump in the rates of misuse of prescription stimulants over the past four years is linked to lax attitudes on the part of parents, according to a new study, though misuse and abuse of prescription opioids has remained flat.

January 14, 2013

A new drug for treating attention deficit hyperactivity disorder made by Pfizer is now available, the drug maker said.

NEW YORK — A new drug for treating attention deficit hyperactivity disorder made by Pfizer is now available, the drug maker said.

Pfizer announced the availability of Quillivant XR (methylphenidate hydrochloride) extended-release oral suspension, calling it the first once-per-day, extended-release liquid formulation of methylphenidate. The Food and Drug Administration approved the drug in September 2012.

October 22, 2012

Pfizer is buying the maker of an attention deficit hyperactivity disorder drug for almost $700 million, Pfizer said Monday.

NEW YORK — Pfizer is buying the maker of an attention deficit hyperactivity disorder drug for almost $700 million, Pfizer said Monday.

The drug maker announced that it would buy privately owned NextWave Pharmaceuticals, which makes the extended-release ADHD drug Quillivant XR (methylphenidate hydrochloride), which the Food and Drug Administration approved last month. The drug is expected to appear in pharmacies in January 2013.

September 14, 2012

Two generic drug makers have settled with a subsidiary of Johnson & Johnson and another company concerning a drug used to treat attention deficit hyperactivity disorder.

HAYWARD, Calif. — Two generic drug makers have settled with a subsidiary of Johnson & Johnson and another company concerning a drug used to treat attention deficit hyperactivity disorder.

Impax Labs and Teva Pharmaceuticals USA had settled a patent infringement suit with Janssen Pharmaceuticals and Alza over Concerta (methylphenidate hydrochloride) extended-release tablets in the 18-mg, 27-mg, 36-mg and 54-mg strengths.

July 18, 2012

Teva Pharmaceuticals has introduced a generic drug for treating attention deficit hyperactivity disorder, the company said.

NORTH WALES, Pa. — Teva Pharmaceuticals has introduced a generic drug for treating attention deficit hyperactivity disorder, the company said.

Teva announced the launch of methylphenidate hydrochloride extended-release capsules in the 20-mg, 30-mg and 40-mg strength. The drug, a generic version of Novartis' Ritalin, is available in 100-pill bottles.

January 4, 2012

The Food and Drug Administration has approved a generic version of a drug for attention deficit hyperactivity disorder made by Actavis, the drug maker said Wednesday.

MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic version of a drug for attention deficit hyperactivity disorder made by Actavis, the drug maker said Wednesday.

May 23, 2011

The FDA has approved a new treatment for Type 2 diabetes, the agency said. The FDA announced the approval of Tradjenta (linagliptin) made by Indianapolis-based Eli Lilly and German drug maker Boehringer Ingelheim.


SUPPLIER NEWS — The FDA has approved a new treatment for Type 2 diabetes, the agency said. The FDA announced the approval of Tradjenta (linagliptin) made by Indianapolis-based Eli Lilly and German drug maker Boehringer Ingelheim.


May 2, 2011

Watson Pharmaceuticals has launched an authorized generic version of a Johnson & Johnson drug for treating attention deficit hyperactivity disorder through a subsidiary, Watson said Monday.

PARSIPPANY, N.J. — Watson Pharmaceuticals has launched an authorized generic version of a Johnson & Johnson drug for treating attention deficit hyperactivity disorder through a subsidiary, Watson said Monday.

Watson announced the launch by Watson Labs of methylphenidate hydrochloride extended-release tablets under an agreement with J&J subsidiary Ortho-McNeil-Janssen.

November 30, 2010

A generic version of a drug indicated to treat attention deficit hyperactivity disorder has hit a roadblock.

HAYWARD, Calif. — A generic version of a drug indicated to treat attention deficit hyperactivity disorder has hit a roadblock.

November 1, 2010

Generic drug maker Watson Pharmaceuticals will distribute an authorized generic version of a drug used...

MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals will distribute an authorized generic version of a drug used to treat attention deficit hyperactivity disorder, Watson said Tuesday.

Watson entered an agreement with Johnson & Johnson subsidiary Ortho-McNeil-Janssen Pharmaceuticals to distribute an authorized generic of Concerta (methylphenidate hydrochloride) extended-release tablets. An authorized generic is a branded drug sold under its generic name, usually by a third-party company.